Version 1
: Received: 21 August 2024 / Approved: 21 August 2024 / Online: 21 August 2024 (11:40:38 CEST)
Version 2
: Received: 20 September 2024 / Approved: 20 September 2024 / Online: 23 September 2024 (07:44:02 CEST)
How to cite:
Markab, O.; Lafi, Z.; Shalan, N.; Al Daghistani, H.; Fahadawi, A.; Madi, R. Advanced Delivery of Curcumin and Nicotinamide: Promising Solutions for Skin Infections and Melanoma. Preprints2024, 2024081541. https://doi.org/10.20944/preprints202408.1541.v2
Markab, O.; Lafi, Z.; Shalan, N.; Al Daghistani, H.; Fahadawi, A.; Madi, R. Advanced Delivery of Curcumin and Nicotinamide: Promising Solutions for Skin Infections and Melanoma. Preprints 2024, 2024081541. https://doi.org/10.20944/preprints202408.1541.v2
Markab, O.; Lafi, Z.; Shalan, N.; Al Daghistani, H.; Fahadawi, A.; Madi, R. Advanced Delivery of Curcumin and Nicotinamide: Promising Solutions for Skin Infections and Melanoma. Preprints2024, 2024081541. https://doi.org/10.20944/preprints202408.1541.v2
APA Style
Markab, O., Lafi, Z., Shalan, N., Al Daghistani, H., Fahadawi, A., & Madi, R. (2024). Advanced Delivery of Curcumin and Nicotinamide: Promising Solutions for Skin Infections and Melanoma. Preprints. https://doi.org/10.20944/preprints202408.1541.v2
Chicago/Turabian Style
Markab, O., Ali Fahadawi and Razan Madi. 2024 "Advanced Delivery of Curcumin and Nicotinamide: Promising Solutions for Skin Infections and Melanoma" Preprints. https://doi.org/10.20944/preprints202408.1541.v2
Abstract
The interest in natural remedies in modern medicine has revealed potent disease-fighting agents, such asCUR(CUR) and nicotinamide (NIC), known for their antioxidant, anti-inflammatory, and immune-boosting properties. This study explores the antibacterial and antimelanoma potential of a CUR-NIC combination and its liposomal formulation. The antibacterial efficacy was assessed against skin infection-causing bacteria, Staphylococcus aureus, while cytotoxicity and migration assays were conducted on the melanoma B16 cancer cell line. The CUR-NIC combination (1:1) demonstrated an inhibition zone of 18±0.8 mm against S. aureus and a MIC of 31.25 µg/ml, outperforming CUR alone. Whereas Lip-CUR-NIC showed an inhibition zone of 12±0.8 mm against S. aureus and a MIC of 37.5 µg/ml. Notably, the cytotoxicity assay revealed that the CUR-NIC duo synergistically inhibited melanoma cell proliferation (CI<1). Liposomal preparations further enhanced this effect, with Lip-CUR-NIC showing a remarkably low IC50 of 8.5 ± 0.3 µM compared to CUR (IC50= 9.8 ± 2.2 µM) and NIC (IC50=135.95 ± 10.2 µM). These findings highlight the synergistic potential of CUR and NIC, especially in their liposomal form, offering a promising strategy for more effective cancer treatment.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
